CO119 Indirect Treatment Comparison and Cost-Minimization Analysis between Riociguat and Selexipag to WHO Functional Class III Pulmonary Arterial Hipertension (PAH) Patients
Jun 1, 2024, 00:00
10.1016/j.jval.2024.03.207
https://www.valueinhealthjournal.com/article/S1098-3015(24)00322-X/fulltext
Title :
CO119 Indirect Treatment Comparison and Cost-Minimization Analysis between Riociguat and Selexipag to WHO Functional Class III Pulmonary Arterial Hipertension (PAH) Patients
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(24)00322-X&doi=10.1016/j.jval.2024.03.207
First page :
Section Title :
Open access? :
No
Section Order :
11419